FDA okays reverse-flow anti-emboli device trial
This article was originally published in Clinica
Executive Summary
ArteriA Medical Science has gained approval from the US FDA to begin a clinical trial of what it claims is the first embolic protection device that eliminates the risk of stroke associated with carotid revascularisation procedures. The company says that its device uses a technique that avoids the release of emboli associated with competitive devices.